Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Vasculitis
Is a persistently elevated IgE level clinically relevant in a patient who has otherwise good control of EGPA and completely suppressed eosinophils on mepolizumab?
Related Questions
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
How would you approach management of a patient with mixed cryoglobulinemic vasculitis with predominant skin involvement and no major organ involvement?
How do you interpret a negative ANCA and a low positive PR3?
How soon after starting treatment would you repeat imaging in patients with Takayasu to monitor response and ensure you have the correct diagnosis?
How would you manage a patient on tocilizumab for recently diagnosed severe GCA who developed a bowel obstruction several weeks after the first dose of Tocilizumab?
Would you give IVIG for Rituximab induced immunodeficiency in patients with reduced kidney function from renal GPA?
How would you approach management of a patient with classic GCA symptoms, elevated ESR and improvement with steroids, but negative temporal artery biopsy and CTA imaging without evidence of vasculitis?
How soon after starting treatment for Takayasu arteritis do you decide on the need for any vascular interventions to manage chronic damage?
How would you interpret the presence of both high titer anti-PR3 and anti-MPO antibodies in a pANCA positive patient with evidence of small vessel vasculitis?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
